[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100540647":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":27,"centralContacts":32,"locations":39,"responsibleParty":50,"collaborators":18,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":18,"eligibilityCriteria":58,"healthyVolunteers":54,"sex":59,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":18,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":72,"overallStatus":42,"whyStopped":18,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"National University of Malaysia","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Hydroxychloroquine group","EXPERIMENTAL","Oral hydroxychloroquine 200mg daily will be prescribed to women in this group from recruitment (14-20 weeks) till delivery, in addition to their standard treatment",[13],"Drug: Hydroxychloroquine Oral Tablet",{"label":15,"type":16,"description":17,"interventionNames":18},"Standard treatment group","NO_INTERVENTION","Women will receive standard treatment for diabetes such as metformin and insulin.",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Hydroxychloroquine Oral Tablet","200mg daily",[9],[26],"plaquenil",[28],{"name":29,"affiliation":30,"role":31},"Rahana Abd Rahman","UKM","PRINCIPAL_INVESTIGATOR",[33],{"name":34,"role":35,"phone":36,"phoneExt":37,"email":38},"Rahana Abdul Rahman, MD","CONTACT","039145","5964","drrahana@ukm.edu.my",[40],{"facility":41,"status":42,"city":43,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":18,"geoPoint":18,"contacts":48},"Antenatal clinic, UKM Medical Centre","RECRUITING","Cheras","Kuala Lumpur","56000","Malaysia","MY",[49],{"name":29,"role":35,"phone":18,"phoneExt":18,"email":18},{"type":51,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR","100540647","hydroxychloroquine-in-type-2-diabetes-during-pregnancy-100540647",false,"NCT06319560","Hydroxychloroquine in Type 2 Diabetes During Pregnancy","Hydroxychloroquine as an Adjunct Therapy in the Management of Type 2 Diabetes in Pregnancy: A Randomised Controlled Trial","Inclusion Criteria:\n\n* Singleton\n* Pregnant women with a confirmed diagnosis of type 2 Diabetes Mellitus\n\nExclusion Criteria:\n\n* autoimmune disease such as Systemic Lupus Erythematosus or rheumatic disease\n* chronic kidney disease\n* fetal anomaly\n* women on steroid therapy\n* diabetic retinopathy\n* known thalassaemia or thalassaemia carrier","FEMALE","20 Years","45 Years",{"count":63,"type":64},56,"ESTIMATED","INTERVENTIONAL",[67],"NA","The goal of this clinical trial is to compare the use of hydroxychloroquine as an adjunct to the current treatment of pregnant women with Type 2 diabetes mellitus.\n\nThe main questions it aims to answer are:\n\n* Does hydroxychloroquine improve the pregnancy outcomes in women with type 2 diabetes during pregnancy?\n* Does hydroxychloroquine improve the inflammatory markers in women with type 2 diabetes during pregnancy? Participants will be randomised into the intervention and control group. The control group will be on standard treatment where as the intervention group will receive hydroxychloroquine as an adjunct of standard treatment",[70,71],"Diabetes in Pregnancy","Type 2 Diabetes",[73,74,75],"diabetes","pregnancy","hydroxychloroquine","2025-06-09",{"date":78,"type":79},"2025-06-12","ACTUAL",{"date":81,"type":79},"2024-03-24",{"date":83,"type":64},"2027-01-01",{"name":5,"class":6},1]